P-340: Optimizing dose selection with computer modeling and simulation: application to the vasopeptidase inhibitor m100240
Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) has gained increasing interest in the treatment of hypertension, heart failure and renoprotection. Specifically, M100240, the thioester of the dual ACE/NEP inhibitor MDL100,173, has been evaluated in the man...
Uloženo v:
| Vydáno v: | American journal of hypertension Ročník 17; číslo S1; s. 158A |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Oxford
Oxford University Press
01.05.2004
|
| Témata: | |
| ISSN: | 0895-7061, 1941-7225 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) has gained increasing interest in the treatment of hypertension, heart failure and renoprotection. Specifically, M100240, the thioester of the dual ACE/NEP inhibitor MDL100,173, has been evaluated in the management of hypertension. A model-based analysis including simulations was employed to characterize the relationship between individual M100240 drug exposure and neurohormonal response and to optimize the dose selection for future clinical studies. Sixty-nine healthy subjects and 189 hypertensive patients were studied after oral once daily administration of 2.5, 5, 10, 25 or 50 mg M100240. Pharmacokinetic-biomarker and blood pressure response models were fitted to the data with computer program NONMEM. A direct inhibitory Emax model adequately described the relationship between MDL100,173 concentration and ACE activity. No clear concentration or dose dependent NEP or blood pressure responses were evident. Given a target 90% ACE inhibition, simulation reveals that (i) 50 mg M100240 once daily produces adequate ACE inhibition 24 hours post-dose in only 20% of subjects and (ii) higher and/or more frequent doses on the order of 25 mg three times daily or 50 mg twice daily are required to achieve the target ACE inhibition in at least 50% of patients over 24 hours. Insufficient blood pressure lowering effects were observed in healthy subjects and hypertensive patients due to inadequate ACE and NEP inhibition with once daily oral doses of up to 50 mg of M100240. Divided doses might provide target ACE inhibition in more patients. Am J Hypertens (2004) 17, 158A–158A; doi: 10.1016/j.amjhyper.2004.03.415 |
|---|---|
| AbstractList | Background and Methods: Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) has gained increasing interest in the treatment of hypertension, heart failure and renoprotection. Specifically, M100240, the thioester of the dual ACE/NEP inhibitor MDL100,173, has been evaluated in the management of hypertension. A model-based analysis including simulations was employed to characterize the relationship between individual M100240 drug exposure and neurohormonal response and to optimize the dose selection for future clinical studies. Sixty-nine healthy subjects and 189 hypertensive patients were studied after oral once daily administration of 2.5, 5, 10, 25 or 50 mg M100240. Pharmacokinetic-biomarker and blood pressure response models were fitted to the data with computer program NONMEM.Results: A direct inhibitory Emax model adequately described the relationship between MDL100,173 concentration and ACE activity. No clear concentration or dose dependent NEP or blood pressure responses were evident. Given a target 90% ACE inhibition, simulation reveals that (i) 50 mg M100240 once daily produces adequate ACE inhibition 24 hours post-dose in only 20% of subjects and (ii) higher and/or more frequent doses on the order of 25 mg three times daily or 50 mg twice daily are required to achieve the target ACE inhibition in at least 50% of patients over 24 hours.Conclusions: Insufficient blood pressure lowering effects were observed in healthy subjects and hypertensive patients due to inadequate ACE and NEP inhibition with once daily oral doses of up to 50 mg of M100240. Divided doses might provide target ACE inhibition in more patients. Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) has gained increasing interest in the treatment of hypertension, heart failure and renoprotection. Specifically, M100240, the thioester of the dual ACE/NEP inhibitor MDL100,173, has been evaluated in the management of hypertension. A model-based analysis including simulations was employed to characterize the relationship between individual M100240 drug exposure and neurohormonal response and to optimize the dose selection for future clinical studies. Sixty-nine healthy subjects and 189 hypertensive patients were studied after oral once daily administration of 2.5, 5, 10, 25 or 50 mg M100240. Pharmacokinetic-biomarker and blood pressure response models were fitted to the data with computer program NONMEM. A direct inhibitory Emax model adequately described the relationship between MDL100,173 concentration and ACE activity. No clear concentration or dose dependent NEP or blood pressure responses were evident. Given a target 90% ACE inhibition, simulation reveals that (i) 50 mg M100240 once daily produces adequate ACE inhibition 24 hours post-dose in only 20% of subjects and (ii) higher and/or more frequent doses on the order of 25 mg three times daily or 50 mg twice daily are required to achieve the target ACE inhibition in at least 50% of patients over 24 hours. Insufficient blood pressure lowering effects were observed in healthy subjects and hypertensive patients due to inadequate ACE and NEP inhibition with once daily oral doses of up to 50 mg of M100240. Divided doses might provide target ACE inhibition in more patients. Am J Hypertens (2004) 17, 158A–158A; doi: 10.1016/j.amjhyper.2004.03.415 |
| Author | Haskell, Lloyd P. Pfister, Marc Martin, Nancy E. |
| Author_xml | – sequence: 1 givenname: Marc surname: Pfister fullname: Pfister, Marc organization: Cardiovascular Department, Aventis Pharmaceuticals, Bridgewater, NJ; Medical and Dental School, University of New Jersey, New Brunswick, NJ. USA – sequence: 2 givenname: Nancy E. surname: Martin fullname: Martin, Nancy E. organization: Cardiovascular Department, Aventis Pharmaceuticals, Bridgewater, NJ; Medical and Dental School, University of New Jersey, New Brunswick, NJ. USA – sequence: 3 givenname: Lloyd P. surname: Haskell fullname: Haskell, Lloyd P. organization: Cardiovascular Department, Aventis Pharmaceuticals, Bridgewater, NJ; Medical and Dental School, University of New Jersey, New Brunswick, NJ. USA |
| BookMark | eNotzUlLxEAQhuFGFByXvyANnhOr0ksSbzK4ouiAB_ESatI9To9JOqZ71PHXG5dT8cHDW3tsu_OdZewIIUVAfbJKqV0tN70d0gxApiBSiWqLTbCUmORZprbZBIpSJTlo3GV7IaxghFrjhH09JELCKb_vo2vdl-teuPHB8mAbW0fnO_7h4pLXvu3X0Q689cY2P4o6w4Nr1w39qFNOfd-4-nfw6HlcWv5Owfd2DBsai65burmLfmwgQCbhgO0sqAn28P_us8eL88fpVXJ7f3k9PbtNnNZlUghUwoCymkwBBS50bmluUNdzSWR0RsKKeYE1QVmUYHJpajJyUaAqi1yT2GfHf9l-8G9rG2K18uuhGz9WCJlWUmFejir5Uy5E-1n1g2tp2FQ0vFY6F7mqrp6eqwwvxOxuOqtuxDezSHNj |
| CODEN | AJHYE6 |
| ContentType | Journal Article |
| Copyright | Copyright Nature Publishing Group May 2004 |
| Copyright_xml | – notice: Copyright Nature Publishing Group May 2004 |
| DBID | BSCLL 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS |
| DOI | 10.1016/j.amjhyper.2004.03.415 |
| DatabaseName | Istex ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China |
| DatabaseTitle | ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
| DatabaseTitleList | ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1941-7225 |
| EndPage | 158A |
| ExternalDocumentID | 2712476861 ark_67375_HXZ_21F3QMCQ_J |
| GroupedDBID | --- --K .2P .55 .GJ .I3 .ZR 0R~ 1B1 1TH 1~5 23M 39C 4.4 48X 4G. 53G 5GY 5RE 5VS 5WD 7-5 70F 7X7 88E 8FI 8FJ AABZA AACZT AAEDT AAFWJ AAJKP AAJQQ AALRI AAMVS AAOGV AAPGJ AAPQZ AAPXW AAQXK AARHZ AAUAY AAUQX AAVAP AAWDT AAXUO ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABMAC ABNGD ABNHQ ABNKS ABOCM ABPQP ABPTD ABQLI ABQNK ABSMQ ABUWG ABVGC ABWST ABWVN ABXVV ABZBJ ACFRR ACGFS ACIUM ACRPL ACUFI ACUKT ACUTJ ACUTO ACVCV ACVFH ACYHN ACZBC ADBBV ADCNI ADEYI ADGZP ADHKW ADHZD ADIPN ADMTO ADMUD ADNBA ADNMO ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPX AEWNT AFFNX AFFQV AFFZL AFIYH AFKRA AFOFC AFPUW AFXAL AFYAG AGINJ AGKRT AGMDO AGORE AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIGII AITUG AJBYB AJDVS AJEEA AJNCP AKRWK ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH AQDSO AQKUS ASPBG ATGXG AVNTJ AVWKF AXUDD AZFZN BAYMD BCRHZ BENPR BEYMZ BHONS BPHCQ BSCLL BTRTY BVRKM BVXVI BZKNY C45 CAG CCPQU CDBKE COF CS3 DAKXR DILTD D~K EBS EE~ EIHJH EJD EMOBN ENERS EO8 F5P F9B FDB FECEO FEDTE FGOYB FLUFQ FOEOM FOTVD FQBLK FYUFA G-Q GAUVT GJXCC H13 H5~ HAR HMCUK HVGLF HW0 HZ~ IHE J21 JSO JXSIZ KBUDW KOP KSI KSN M1P M41 MBLQV MHKGH ML0 NGC NOMLY NOYVH NQ- NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OCZFY ODMLO OJQWA OJZSN OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q1. Q5Y R2- ROL ROX ROZ RPZ RUSNO RW1 RXO SDP SSZ TEORI TJX TMA UKHRP WH7 X7M XPP YAYTL YKOAZ YXANX YYP ZGI ZXP 3V. 7XB 8FK 9DU AFFHD K9. PKEHL PQEST PQUKI PRINS |
| ID | FETCH-LOGICAL-i669-83153d05e6ad8081f67eabd16cb4aad62a3e3b81ca09890d74dcad4f8159876a3 |
| IEDL.DBID | 7X7 |
| ISSN | 0895-7061 |
| IngestDate | Sat Nov 29 14:21:39 EST 2025 Sat Sep 20 11:01:34 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | S1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-i669-83153d05e6ad8081f67eabd16cb4aad62a3e3b81ca09890d74dcad4f8159876a3 |
| Notes | ark:/67375/HXZ-21F3QMCQ-J href:17_S1_158Aa.pdf istex:6EB2DEA3ABA1C4747C45DCAF1CC785607EA0EF5C ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 |
| PQID | 1026545179 |
| PQPubID | 536305 |
| ParticipantIDs | proquest_journals_1026545179 istex_primary_ark_67375_HXZ_21F3QMCQ_J |
| PublicationCentury | 2000 |
| PublicationDate | 2004-05 20040501 |
| PublicationDateYYYYMMDD | 2004-05-01 |
| PublicationDate_xml | – month: 05 year: 2004 text: 2004-05 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford |
| PublicationTitle | American journal of hypertension |
| PublicationTitleAlternate | AJH |
| PublicationYear | 2004 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| SSID | ssj0004661 |
| Score | 1.70308 |
| Snippet | Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) has gained increasing interest in the treatment of hypertension,... Background and Methods: Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) has gained increasing interest in the... |
| SourceID | proquest istex |
| SourceType | Aggregation Database Publisher |
| StartPage | 158A |
| SubjectTerms | ACE Inhibition Computer Modeling NEP Inhibition |
| Title | P-340: Optimizing dose selection with computer modeling and simulation: application to the vasopeptidase inhibitor m100240 |
| URI | https://api.istex.fr/ark:/67375/HXZ-21F3QMCQ-J/fulltext.pdf https://www.proquest.com/docview/1026545179 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1941-7225 dateEnd: 20151231 omitProxy: false ssIdentifier: ssj0004661 issn: 0895-7061 databaseCode: 7X7 dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1941-7225 dateEnd: 20151231 omitProxy: false ssIdentifier: ssj0004661 issn: 0895-7061 databaseCode: BENPR dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NSyQxEA2uI4sXdd0Vv8lBvGXp7nx1vIiKgwiO4-Jh8NKkkwy2Mt3j9Cjir7eSiTgg7MVzh6aprryqVFXeQ-hAZdxxYTTRuaRwQEkFUcOME-vRMqPUcTcTm5C9Xj4YqH4suLVxrPIDEwNQ28b4Gjns7kxAtAf_OR4_Ea8a5burUULjB-p42Wzv53Ig5-5FBr7UJFecSAhcczeEH_7q0cM9HPUCJyjzRKfMS-N2vHFfvwBziDbd1e9-5xpaiXkmPpk5xi-04Op19PMqdtJ_o7c-oSw5wtcAGaPqDQIYtk3rcBt0ceBnYV-hxSaKPuCgmONX6drithpF1a8jPNcBx9MGQz6JX3TbjP20jIUQiav6vioBN-AdaeA6-4Nuu-e3Zxck6jCQSghFcgqoaBPuhLZep2MopNOlTYUpmdZWZJo6Wuap0YnKVWIls0ZbNswhUwKs1XQDLdZN7TYRtiqFhTw3mjtGkxIcRAumUsNkwpOh2UKHwf7FeEa1UejJo588k7y4GNwVWdqlN1dnN8XlFtr9sH4RN11bfJp--_-Pd9DybADHzy3uosXp5NntoSXzMq3ayX7woX3UOT3v9f-9A0PK0Q4 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwELVKi6AXPosoFPABuBkl8VdcqaqqwmpLu0sr7WHFxXJsr5qiTbabpdD-J_4jYycrVkLi1gPnWJaceX7jsWfmIfRWZdxzYQ0xuaQQoKSCqEnGiQtsmVHquW_FJuRwmI_H6nQN_VrWwoS0yiUnRqJ2tQ135LC7MwHeHvCzP7skQTUqvK4uJTRaWBz76x8QsjV7Rx_Bvu-yrPdpdNgnnaoAKYVQJKewx13CvTAuqE5MhPSmcKmwBTPGicxQT4s8tSZRuUqcZM4axyY5-H1gDkNh2jtoA2hchlhPjuVKGWZsz5rkihMJfnKlIPnig5lenENkGVuQstBXlQUl3o1gy59_-YHo3HoP_7Pf8gg96E7R-KCF_WO05qsn6N6gyxN4im5OCWXJLv4ChDgtb8A9Y1c3HjdR9QegiMP9M7adpAWOekBhlKkcbsppp2m2i1fe9_GixnBaxlemqWchF8jBAQCX1XlZACvCHGns5LaFRrex8Gdovaor_xxhp1IYyHNruGc0KQD-RjCVWiYTnkzsNnofza1nbSMRbebfQl6d5Lo__qqztEfPBodn-vM22lkaW3eU0ug_ln7x789v0P3-aHCiT46Gxy_RZptqFDI0d9D6Yv7dv0J37dWibOavI3wx0reMi98JciwK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=P-340%3A+Optimizing+dose+selection+with+computer+modeling+and+simulation%3A+application+to+the+vasopeptidase+inhibitor+m100240&rft.jtitle=American+journal+of+hypertension&rft.au=Pfister%2C+Marc&rft.au=Martin%2C+Nancy+E.&rft.au=Haskell%2C+Lloyd+P.&rft.date=2004-05-01&rft.pub=Oxford+University+Press&rft.issn=0895-7061&rft.eissn=1941-7225&rft.volume=17&rft.issue=S1&rft.spage=158A&rft.epage=158A&rft_id=info:doi/10.1016%2Fj.amjhyper.2004.03.415&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_HXZ_21F3QMCQ_J |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0895-7061&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0895-7061&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0895-7061&client=summon |